

# Claudine C Duvivier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/333201/publications.pdf>

Version: 2024-02-01

22  
papers

535  
citations

933447

10  
h-index

713466

21  
g-index

22  
all docs

22  
docs citations

22  
times ranked

781  
citing authors

#	ARTICLE	IF	CITATIONS
1	A large French prospective cohort of HIV-infected patients: the Nadis Cohort. <i>HIV Medicine</i> , 2009, 10, 504-511.	2.2	118
2	Ageing and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , 2018, 32, 2405-2416.	2.2	83
3	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13) Tj ETQq1 1 0.784314 rgBT /Overlock 179	2.9	79
4	Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. <i>PLoS ONE</i> , 2018, 13, e0203895.	2.5	50
5	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients " French ANRS CO13 HEPAVIH cohort. <i>Journal of Hepatology</i> , 2017, 67, 23-31.	3.7	45
6	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
7	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1648-1652.	3.0	29
8	Spectrum and Incidence Trends of AIDS- and Non-AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 554-563.	2.5	21
9	Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection. <i>PLoS ONE</i> , 2019, 14, e0215464.	2.5	17
10	Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3425-3434.	3.0	14
11	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS-CO13 HEPAVIH). <i>Journal of Hepatology</i> , 2020, 72, 588-591.	3.7	7
12	Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV. <i>Journal of Infectious Diseases</i> , 2020, 221, 516-522.	4.0	7
13	Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients. <i>Infectious Diseases</i> , 2016, 48, 392-398.	2.8	6
14	High syphilis prevalence and incidence in people living with HIV and Preexposure Prophylaxis users: A retrospective review in the French Dat'AIDS cohort. <i>PLoS ONE</i> , 2022, 17, e0268670.	2.5	6
15	Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France. <i>PLoS ONE</i> , 2022, 17, e0261069.	2.5	4
16	HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. <i>HIV Medicine</i> , 2022, 23, 684-692.	2.2	4
17	Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study: Figure 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2418-2420.	3.0	3
18	Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort. <i>PLoS ONE</i> , 2018, 13, e0208657.	2.5	3

#	ARTICLE	IF	CITATIONS
19	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	2.2	2
20	No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy. <i>HIV Medicine</i> , 2022, 23, 301-306.	2.2	1
21	Raltegravir 1200mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial. <i>AIDS Research and Therapy</i> , 2022, 19, 4.	1.7	1
22	Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 477-481.	3.0	0